Go to: content | top | bottom | search
 
 
You are hereUNIL > Department of Biochemistry > Research > Mach Jean-Pierre

Mach Jean-Pierre, Professor Emeritus


 

Biography

Jean-Pierre Mach received his medical degree at the University of Geneva and trained from 1963 to 1967 as a postdoctoral fellow at the Massachussetts General Hospital in Boston. He specialized in the field of tumor markers at the Department of Biochemistry of our University where he became professor in 1976. From 1978 to 1986, he was associate director of the Lausanne branch from the Ludwig Institute. At his retirement from a double appointment at ISREC and our University, he joined Prof. G. Corradin's group to pursue his research with Dr Alena Donda, project leader, on antibody-mediated targeting of antigenic MHC class I complexes and MHC related molecules on tumor cells.

Research Interests

CANCER: ANTIBODY-MEDIATED TUMOR TARGETING OF MHC-RELATED MOLECULE CD1d

Taking advantage of our experience in tumor targeting with antibodies and in T lymphocyte cytotoxicity, we designed a new type of conjugates, consisting of antibody fragments coupled to Major Histocompatibility Complexes (MHC) or to the MHC-related molecule CD1d. Regarding the tumor targeting of classical MHC, we demonstrated that Fab fragments from different anti-tumor marker antibodies, conjugated to MHC/viral peptides, can target these antigens on the surface of cancer cells and induce their efficient lysis by virus specific cytotoxic T lymphocytes. We developed several in vivo syngeneic tumor models in viral infected mice and demonstrated the feasibility of this new immunotherapy strategy. In view of these promising results, we developed similar approaches applied to the non-polymorphic MHC related molecules CD1d, in order to redirect NKT cells to the tumor site. NKT cells are a unique subpopulation of T lymphocytes recognizing glycolipid antigens in the context of the MHC class I-like monomorphic molecule CD1d. Upon activation, iNKT cells are known to induce in turn a potent activation of cells of the innate and adaptive immune response, such as NK cells, dendritic cells (DCs), as well as T and B lymphocytes. In this context, iNKT cells have been shown to efficiently mediate antitumor activity.

Fig. 1: NKT cells as transactivators of the innate and adaptive immune response. The glycolipid ligand α-GalCer presented by CD1d expressed on DC will activate NKT cells. In turn, activated NKT cells will rapidly secrete IFNγ and upregulate CD40L. These events will lead to NK activation, DC maturation and subsequent development of antigen-specific T lymphocytes, possibly against an existing tumor.

Antibody-CD1d bifunctional fusion protein for targeting innate immunity to cancer cells

Invariant natural killer T lymphocytes (iNKT) are a unique subpopulation of T lymphocytes recognizing glycolipid antigens in the context of the MHC class I-like monomorphic molecule CD1d. Upon activation, iNKT cells are known to induce in turn a potent activation of cells of the innate and adaptive immune response, such as NK cells, dendritic cells (DCs), as well as T and B lymphocytes. In this context, iNKT cells have been shown to efficiently mediate antitumor activity. Thus, recent research has focused on the manipulation of these cells for antitumor therapies. Alpha-galactosylceramide (αGalCer) is a synthetic high affinity CD1d ligand used for activation of iNKT cells, and has been tested for therapy of cancer patients in clinical trials. However, a major drawback of αGalCer, as a free drug, is that a single injection leads to a short-lived iNKT cell activation followed by a long-term anergy, limiting its therapeutic use.

In contrast, we have recently (Stirnemann et al. 2008) shown that, when αGalCer was loaded on a recombinant soluble CD1d molecule (αGalCer/sCD1d), repeated injections led to a sustained iNKT and NK cell activation associated with interferon γ secretion, as well as with DC maturation. Most importantly, when the αGalCer/sCD1d was fused to an anti-HER2 scFv antibody fragment, potent inhibition of experimental lung metastasis and established subcutaneous tumors was obtained, when systemic treatment was started 7 days after tumor graft, whereas at this time, free αGalCer had no effect. The anti-tumor activity of the CD1d-anti-HER2 fusion protein was associated with its HER2-specific tumor localization and with the accumulation of iNKT, NK and T cells at the tumor site.

These results suggest the enormous potential of targeting these recombinant CD1d proteins to tumors for effective immunotherapy approaches. The aim of this project is to continue the preclinical development of this tool with a view to its future clinical development in the context of current immunotherapy cancer programs underway in the Lausanne environment.

New developments:

Potential of the sustained iNKT and NK cell activation in promoting active antitumor immunization. The characterization of tumor antigens has promoted the development of cancer vaccines. However, despite good antigen-specific T cell responses, clinical results have remained limited, largely due to T cell tolerance at the tumor site. We have now started collaboration with Prof. Pedro Romero at the LICR to combine sCD1d-antitumor therapy with active immunization against melanoma antigens, such as TRP2 or GP100.

Understand the mechanism of the sustained iNKT cell activation that is obtained by repeated injections of recombinant αGalCer-loaded sCD1d molecules, in contrast to the short-lived activation induced by treatment with αGalCer alone, which is followed by long-term unresponsiveness. Interestingly, it was recently shown that the co-inhibitory receptor Program death-1 (PD-1) was mainly responsible for iNKT anergy. In contrast, our recent results indicate that iNKT cells activation by recombinant αGalCer-loaded CD1d proteins prevent PD-1 upregulation resulting in the prolonged reactivity of these cells.

Immunosuppressive mechanisms at the tumor site. Multiple roles have been ascribed to T regulatory cells (Tregs) and to Myeloid Derived Suppressor Cells (MDSCs) in repressing antitumor immunity and promoting tumor growth, and these two cell populations are often enriched in tumor tissue. Two mouse models, that have been developed to selectively deplete these cell populations, will be tested to evaluate their respective roles in limiting CD1d-mediated therapy:

  • DEREG mice: this transgenic mouse line expresses the diphteria toxin receptor under the control of the FoxP3 promoter. Administration of diphteria toxin allows the transient depletion of Tregs cells. This model will be tested in collaboration with Pr. A. Knuth and Dr. Maries van den Broek, Oncology Department, University Hospital Zurich. It will allow evaluating the limiting role of Tregs on the efficacy of the CD1d treatment.
     
  • Arginase 1 knock out mice within the myeloid and endothelial lineages have recently been developed by specific deletion under the Tie2 Cre promoter (Maastricht University). Arginase 1 activity is one of the major mechanisms of MDSCs to induce T cell immunosuppression. This mouse model will allow evaluating the inhibitory role of MDSCs on the iNKT/NK-mediated CD1d immunotherapy.

Combine sCD1d-antitumor therapy with low dose chemotherapy. Recent studies have shown that low dose chemotherapy had immunostimulatory properties, and some agents were shown to act against T regs and MDSCs. Our preliminary data demonstrate a potent synergy between iNKT-mediated antitumor therapy and low dose cyclophosphamide (CY).

Newly developed sCD1d-antitumor fusion proteins. So far, two sCD1d-antitumor scFv fusion proteins were developed and shown to have antitumor activity, respectively sCD1d-anti-HER2 (Stirnemann et al. 2008) and sCD1d-anti-CEA fusion proteins (manuscript in prep). Alternatively to the targeting of CD1d to tumor antigens, antigens expressed by the tumor stroma or by tumor neo-vessels are considered. In this context, a fusion protein of b2m-sCD1d-anti-VEGFR3 was developed and shown to bind efficiently on VEGFR-3-expressing cells. This approach may allow redirecting the iNKT-mediated immune response inside various tumors, whose neo-vessels are known to express VEGFR-3, independently of their own phenotype.

Tumor models. The different studies are performed in various tumor models:
Grafted tumors: subcutaneous or i.v. tumor grafts (melanoma, colon carcinoma)
Spontaneous tumors: transgenic model of Tyr::N-Ras autochtonous melanomas

TOP ^


2016 |  2014 |  2013 |  2012 |  2011 |  2010 |  2009 |  2008 |  2007 |  2006 |  2005 |  2004 |  2003 |  2002 |  2001 |  2000 |  1999 |  1998 |  1997 |  1996 |  1995 |  1994 |  1993 |  1992 |  1991 |  1990 |  1989 |  1988 |  1987 |  1986 |  1985 |  1984 |  1983 |  1982 |  1981 |  1980 |  1979 |  1978 |  1977 |  1976 |  1975 |  1974 |  1973 |  1972 |  1971 |  1970 |  1969 | 
 

2016
Golay J., Choblet S., Iwaszkiewicz J., Cérutti P., Ozil A., Loisel S., Pugnière M., Ubiali G., Zoete V., Michielin O. et al., 2016. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. Journal of Immunology 196(7) pp. 3199-3211. [DOI] [Web of Science] [Pubmed]
Zhang L., Tschumi B.O., Lopez-Mejia I.C., Oberle S.G., Meyer M., Samson G., Rüegg M.A., Hall M.N., Fajas L., Zehn D. et al., 2016. Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner. Cell Reports 14(5) pp. 1206-1217. [DOI] [Web of Science] [Pubmed]
2014
Corgnac S., Perret R., Zhang L., Mach J.P., Romero P., Donda A., 2014. iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. Journal for Immunotherapy of Cancer 2(1) p. 39. [DOI] [Pubmed]
Engelhardt N., Mach J.P., 2014. In memory of Garry Abelev 1928-2013. Tumour Biology 35(7) pp. 6169-6173. [DOI] [Web of Science] [Pubmed]
Galluzzi L., Vacchelli E., Bravo-San Pedro J.M., Buqué A., Senovilla L., Baracco E.E., Bloy N., Castoldi F., Abastado J.P., Agostinis P. et al., 2014. Classification of current anticancer immunotherapies. Oncotarget 5(24) pp. 12472-12508. [Web of Science] [Pubmed]
Zhang L., Tschumi B.O., Corgnac S., Rüegg M.A., Hall M.N., Mach J.P., Romero P., Donda A., 2014. Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function. Journal of Immunology 193(4) pp. 1759-1765. [DOI] [Web of Science] [Pubmed]
2013
Buchegger F., Larson S.M., Mach J.P., Chalandon Y., Dietrich P.Y., Cairoli A., Prior J.O., Romero P., Speiser D.E., 2013. Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. Clinical and Developmental Immunology 2013 p. 875343. [Document] [DOI] [Web of Science] [Pubmed]
Buchegger F., Mach J.P., Press O.W., Bischof Delaloye A., Larson S.M., Prior J.O., Ketterer N., 2013. Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies? Annals of Oncology 24(7) pp. 1948-1949. [Document] [DOI] [Web of Science] [Pubmed]
Corgnac S., Perret R., Derré L., Zhang L., Stirnemann K., Zauderer M., Speiser D.E., Mach J.P., Romero P., Donda A., 2013. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunology, Immunotherapy 62(4) pp. 747-760. [Document] [DOI] [Web of Science] [Pubmed]
2012
Larbouret C., Gaborit N., Chardès T., Coelho M., Campigna E., Bascoul-Mollevi C., Mach J.P., Azria D., Robert B., Pèlegrin A., 2012. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia 14(2) pp. 121-130. [Web of Science] [Pubmed]
Mach J.P., 2012. Introduction to monoclonal antibodies. Cancer Immunity 12 p. 11. [Document] [url editor site] [Pubmed]
2011
Loisel S., André P.A., Golay J., Buchegger F., Kadouche J., Cérutti M., Bologna L., Kosinski M., Viertl D., Delaloye A.B. et al., 2011. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. Molecular Cancer 10 p. 42. [Document] [DOI] [Web of Science] [Pubmed]
2010
Golay J., Bologna L., André P.A., Buchegger F., Mach J.P., Boumsell L., Introna M., 2010. Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 116(17) pp. 3372-3373. [DOI] [Web of Science] [Pubmed]
Larbouret C., Robert B., Bascoul-Mollevi C., Penault-Llorca F., Ho-Pun-Cheung A., Morisseau S., Navarro-Teulon I., Mach J.P., Pèlegrin A., Azria D., 2010. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Annals of Oncology 21(1) pp. 98-103. [DOI] [Web of Science] [Pubmed]
2009
Kerth A., Garidel P., Howe J., Alexander C., Mach J.P., Waelli T., Blume A., Rietschel E.Th., Brandenburg K., 2009. An infrared reflection-absorption spectroscopic (IRRAS) study of the interaction of lipid A and lipopolysaccharide Re with endotoxin-binding proteins. Medicinal Chemistry 5(6) pp. 535-542. [DOI] [Web of Science] [Pubmed]
Khatri I., Alexander C., Brandenburg K., Fournier K., Mach J.P., Rietschel E.T., Ulmer A.J., Terzioglu E., Waelli T., Gorczynski R.M., 2009. Induction of tolerogenic vs immunogenic dendritic cells (DCs) in the presence of GM-CSF is regulated by the strength of signaling from monophosphoryl lipid A (MPLA) in association with glutathione and fetal hemoglobin gamma-chain. Immunology letters 124(1) pp. 44-49. [DOI] [Web of Science] [Pubmed]
2008
Germain C., Campigna E., Salhi I., Morisseau S., Navarro-Teulon I., Mach J.P., Pèlegrin A., Robert B., 2008. Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. Protein engineering, design and selection 21(11) pp. 665-672. [Document] [DOI] [Web of Science] [Pubmed]
Howe J., Garidel P., Roessle M., Richter W., Alexander C., Fournier K., Mach J.P., Waelli T., Gorczynski R.M., Ulmer A.J. et al., 2008. Structural investigations into the interaction of hemoglobin and part structures with bacterial endotoxins. Innate immunity 14(1) pp. 39-49. [DOI] [Web of Science] [Pubmed]
Howe J., Richter W., Hawkins L., Rössle M., Alexander C., Fournier K., Mach J.P., Waelli T., Gorczynski R.M., Ulmer A.J. et al., 2008. Hemoglobin enhances the biological activity of synthetic and natural bacterial (endotoxic) virulence factors: a general principle. Medicinal chemistry 4(6) pp. 520-525. [DOI] [Web of Science] [Pubmed]
Khatri I., Alexander C., Brandenburg K., Fournier K., Lee L., Mach J.P., Rietschel E.T., Ulmer A.J., Waelli T., Gorczynski R.M., 2008. A role for altered TLR gene expression in association with increased expression of CD200R in the induction of mucosal tissue CD4(+) Treg in aged mice following gavage with a liver extract along with intramuscular monophosphoryl lipid A (MPLA) injection. Experimental gerontology 43(8) pp. 771-781. [DOI] [Web of Science] [Pubmed]
Stirnemann K., Romero J. F., Baldi L., Robert B., Cesson V., Besra G. S., Zauderer M., Wurm F., Corradin G., Mach J. P. et al., 2008. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. Journal of Clinical Investigation 118(3) pp. 994-1005. [DOI] [Web of Science] [Pubmed]
Ychou M., Azria D., Menkarios C., Faurous P., Quenet F., Saint-Aubert B., Rouanet P., Pèlegrin M., Bascoul-Mollevi C., Guerreau D. et al., 2008. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clinical cancer research 14(11) pp. 3487-3493. [DOI] [Web of Science] [Pubmed]
2007
Gorczynski R.M., Alexander C., Bessler W., Brandenburg K., Fournier K., Mach J.P., Mueller S., Rietschel E.T., Ulmer A.J., Waelli T. et al., 2007. An alteration in the levels of populations of CD4+ Treg is in part responsible for altered cytokine production by cells of aged mice which follows injection with a fetal liver extract. Immunology letters 109(2) pp. 101-112. [DOI] [Web of Science] [Pubmed]
Howe J., Hammer M., Alexander C., Rössle M., Fournier K., Mach J.P., Waelli T., Gorczynski R.M., Ulmer A.J., Zähringer U. et al., 2007. Biophysical characterization of the interaction of endotoxins with hemoglobins. Medicinal chemistry 3(1) pp. 13-20. [DOI] [Web of Science] [Pubmed]
Larbouret C., Robert B., Navarro-Teulon I., Thèzenas S., Ladjemi M.Z., Morisseau S., Campigna E., Bibeau F., Mach J.P., Pèlegrin A. et al., 2007. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clinical Cancer Research 13(11) pp. 3356-3362. [DOI] [Web of Science] [Pubmed]
2006
Buchegger F., Antonescu C., Delaloye A.B., Helg C., Kovacsovics T., Kosinski M., Mach J.P., Ketterer N., 2006. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. British journal of cancer 94(12) pp. 1770-1776. [Document] [DOI] [Web of Science] [Pubmed]
Cesson V., Stirnemann K., Robert B., Luescher I., Filleron T., Corradin G., Mach J.P., Donda A., 2006. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates. Clinical cancer research 12(24) pp. 7422-7430. [DOI] [Web of Science] [Pubmed]
Fattah O.M., Cloutier S.M., Kündig C., Felber L.M., Gygi C.M., Jichlinski P., Leisinger H.J., Gauthier E.R., Mach J.P., Deperthes D., 2006. Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells. International Journal of Cancer 119(10) pp. 2455-2463. [DOI] [Web of Science] [Pubmed]
Gorczynski R.M., Alexander C., Bessler W., Brandenburg K., Fournier K., Hoffmann P., Mach J.P., Mueller S., Rietschel E.T., Terzioglu E. et al., 2006. Role of MIF and glutathione, in association with fetal ovine globin chain (Hbgamma) and LPS, in induction of TNFalpha from cells of young and aged mice, and PBL from healthy human populations. Immunology Letters 105(2) pp. 140-149. [DOI] [Web of Science] [Pubmed]
2005
Germain C., Larbouret C., Cesson V., Donda A., Held W., Mach J.P., Pèlegrin A., Robert B., 2005. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clinical Cancer Research 11(20) pp. 7516-7522. [DOI] [Web of Science] [Pubmed]
Gorczynski R.M., Alexander C., Bessler W., Fournier K., Hoffmann P., Mach J.P., Rietschel E.T., Song L., Waelli T., Westphal O. et al., 2005. Analysis of interaction of cloned human and/or sheep fetal hemoglobin gamma-chain and LPS in augmenting induction of inflammatory cytokine production in vivo and in vitro. Immunology Letters 100(2) pp. 120-129. [DOI] [Web of Science] [Pubmed]
Müller S., Hoffmann P., Esche U.V., Mach J.P., Gorczynski R.M., Waelli T., Alexander C., Zähringer U., Rietschel E.T., Bessler W.G. et al., 2005. A fetal sheep liver extract containing immunostimulatory substances including LPS acts as leukocyte activator in cells of LPS responder and non responder mice. International Immunopharmacology 5(13-14) pp. 1809-1819. [DOI] [Web of Science] [Pubmed]
2004
Buchegger F., Adamer F., Schaffland A.O., Kosinski M., Grannavel C., Dupertuis Y.M., de Tribolet N., Mach J.P., Delaloye A.B., 2004. Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. International Journal of Cancer 110(1) pp. 145-149. [DOI] [Web of Science] [Pubmed]
Gorczynski R.M., Alexander C., Bessler W., Fournier K., Hoffmann P., Mach J.P., Manuel J., Ramakrishna V., Rietschel E.T., Song L. et al., 2004. Characterization of an interaction between fetal hemoglobin and lipid A of LPS resulting in augmented induction of cytokine production in vivo and in vitro. International Immunopharmacology 4(14) pp. 1859-1872. [DOI] [Web of Science] [Pubmed]
2003
2002
Cloutier S.M., Chagas J.R., Mach J.P., Gygi C.M., Leisinger H.J., Deperthes D., 2002. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. European journal of biochemistry / FEBS 269(11) pp. 2747-54. [DOI] [Web of Science] [Pubmed]
2001
Dupertuis Y.M., Vazquez M., Mach J.P., De Tribolet N., Pichard C., Slosman D.O., Buchegger F., 2001. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Research 61(21) pp. 7971-7977. [Web of Science] [Pubmed]
Houimel M., Schneider P., Terskikh A., Mach J.P., 2001. Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. International Journal of Cancer 92(5) pp. 748-755. [DOI] [Web of Science] [Pubmed]
Robert B., Guillaume P., Luescher I., Doucey M.A., Cerottini J.C., Romero P., Mach J.P., 2001. Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments. Cancer Immunity 1(2) pp. 1-13. [url editor site] [Pubmed]
Wong C., Waibel R., Sheets M., Mach J.P., Finnern R., 2001. Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunology, Immunotherapy 50(2) pp. 93-101. [DOI] [Web of Science] [Pubmed]
2000
Buchegger F., Allal A.S., Roth A., Papazyan J.P., Dupertuis Y., Mirimanoff R.O., Gillet M., Pelegrin A., Mach J.P., Slosman D.O., 2000. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study. Anticancer Research 20(3B) pp. 1889-1896. [Web of Science] [Pubmed]
Buchegger F., Roth A., Allal A., Dupertuis Y.M., Slosman D.O., Delaloye A.B., Mach J.P., 2000. Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy. Annals of the New York Academy of Sciences 910 pp. 263-9; discussion 269-70. [DOI] [Web of Science] [Pubmed]
Cloutier S.M., Couty S., Terskikh A., Marguerat L., Crivelli V., Pugnières M., Mani J.C., Leisinger H.J., Mach J.P., Deperthes D., 2000. Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Molecular Immunology 37(17) pp. 1067-1077. [DOI] [Web of Science] [Pubmed]
Gervaz P., Blanchard A., Pampallona S., Mach J.P., Fontolliet C., Gillet M., 2000. Prognostic value of postoperative carcinoembryonic antigen concentration and extent of invasion of resection margins after hepatic resection for colorectal metastases. European Journal of Surgery 166(7) pp. 557-561. [DOI] [Web of Science] [Pubmed]
Pèlegrin A., Xavier F., Barbet J., Bartholeyns J., Baty D., Buchegger F., Chatal J.F., Dufief F., Gurreau D., Gruaz-Guyon A. et al., 2000. Immunociblage des tumeurs: situation et perspectives en 2000. Bulletin du Cancer 87(11) pp. 777-791. [Document] [Web of Science] [Pubmed]
Robert B., Guillaume P., Luescher I., Romero P., Mach J.P., 2000. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. European Journal of Immunology 30(11) pp. 3165-3170. [DOI] [Web of Science] [Pubmed]
1999
Escobar P., Yu Z., Terskikh A., Holmes N., Corradin G., Mach J.P., Healy F., 1999. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein. Clinical and Experimental Immunology 116(2) pp. 214-219. [Web of Science] [Pubmed]
Houimel M., Mach J.P., Corthésy-Theulaz I., Corthésy B., Fisch I., 1999. New inhibitors of Helicobacter pylori urease holoenzyme selected from phage-displayed peptide libraries. European Journal of Biochemistry 262(3) pp. 774-780. [DOI] [Web of Science] [Pubmed]
Leconte A., Garambois V., Ychou M., Robert B., Pourquier D., Terskikh A., Mach J.P., Pèlegrin A., 1999. Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model. British Journal of Cancer 80(9) pp. 1373-1379. [Document] [DOI] [Web of Science] [Pubmed]
Robert B., Dorvillius M., Buchegger F., Garambois V., Mani J.C., Pugnières M., Mach J.P., Pèlegrin A., 1999. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). International Journal of Cancer 81(2) pp. 285-291. [DOI] [Web of Science] [Pubmed]
Waibel R., Alberto R., Willuda J., Finnern R., Schibli R., Stichelberger A., Egli A., Abram U., Mach J.P., Plückthun A. et al., 1999. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nature biotechnology 17(9) pp. 897-901. [DOI] [Web of Science] [Pubmed]
1998
Eberl G., Jiang S., Yu Z., Schneider P., Corradin G., Mach J.P., 1998. An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells. Clinical and Experimental Immunology 114(2) pp. 173-178. [DOI] [Web of Science] [Pubmed]
Westerman P., Glanzmann T., Andrejevic S., Braichotte D.R., Forrer M., Wagnieres G.A., Monnier P., van den Bergh H., Mach J.P., Folli S., 1998. Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. International Journal of Cancer 76(6) pp. 842-850. [DOI] [Web of Science] [Pubmed]
Ychou M., Pelegrin A., Faurous P., Robert B., Saccavini J.C., Guerreau D., Rossi J.F., Fabbro M., Buchegger F., Mach J.P. et al., 1998. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer. International Journal of Cancer 75(4) pp. 615-619. [DOI] [Web of Science] [Pubmed]
1997
Delaloye A.B., Delaloye B., Buchegger F., Vogel C.A., Gillet M., Mach J.P., Smith A., Schubiger P.A., 1997. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. Journal of Nuclear Medicine 38(6) pp. 847-853. [Web of Science] [Pubmed]
Sun L.Q., Vogel C.A., Mirimanoff R.O., Coucke P., Slosman D.O., Mach J.P., Buchegger F., 1997. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Research 57(7) pp. 1312-1319. [Web of Science] [Pubmed]
Terskikh A.V., Le Doussal J.M., Crameri R., Fisch I., Mach J.P., Kajava A.V., 1997. "Peptabody": a new type of high avidity binding protein. Proceedings of the National Academy of Sciences of the United States of America 94(5) pp. 1663-1668. [DOI] [Web of Science] [Pubmed]
1996
Buchegger F., Gillet M., Doenz F., Vogel C.A., Achtari C., Mach J.P., Delaloye B., Delaloye A.B., 1996. Biodistribution of anti-CEA F(ab')2 fragments after intra-arterial and intravenous injection in patients with liver metastases due to colorectal carcinoma. Nuclear Medicine Communications 17(6) pp. 500-503. [DOI] [Web of Science] [Pubmed]
Buchegger F., Mach J.P., Folli S., Delaloye B., Bischof-Delaloye A., Pèlegrin A., 1996. Higher efficiency of 131I-labeled anti-carcinoembryonic antigen-monoclonal antibody F(ab')2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice. Recent Results in Cancer Research 141 pp. 19-35. [Pubmed]
Galmiche M.C., Vogel C.A., Bischof Delaloye A., Schmidt P.M., Healy F., Mach J.P., Buchegger F., 09-1996. Combined effects of interleukin-3 and interleukin-11 on hematopoiesis in irradiated mice. Experimental Hematology 24(11) pp. 1298-306. [Web of Science] [Pubmed]
Robert B., Mach J.P., Mani J.C., Ychou M., Folli S., Artus J.C., Pèlegrin A., 1996. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer research 56(20) pp. 4758-4765. [Web of Science] [Pubmed]
Vogel C.A., Galmiche M.C., Westermann P., Sun L.Q., Pèlegrin A., Folli S., Bischof Delaloye A., Slosman D.O., Mach J.P., Buchegger F., 1996. Carcinoembryonic antigen expression, antibody localisation and immunophotodetection of human colon cancer liver metastases in nude mice: a model for radioimmunotherapy. International Journal of Cancer 67(2) pp. 294-302. [DOI] [Web of Science] [Pubmed]
1995
Buchegger F., Mach J.P., Pèlegrin A., Gillet M., Vogel C.A., Buclin T., Ryser J.E., Delaloye B., Delaloye A.B., 1995. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. Journal of Nuclear Medicine 36(3) pp. 420-429. [Web of Science] [Pubmed]
Frikart L., Fournier K., Mach J.P., Givel J.C., 1995. Potential value of biliary CEA assay in early detection of colorectal adenocarcinoma liver metastases. European Journal of Surgical Oncology 21(3) pp. 276-279. [DOI] [Pubmed]
1994
de Moraes J.Z., Gesztesi J.L., Westermann P., Le Doussal J.M., Lopes J.D., Mach J.P., 1994. Anti-idiotypic monoclonal antibody AB3, reacting with the primary antigen (CEA), can localize in human colon-carcinoma xenografts as efficiently as AB1. International Journal of Cancer 57(4) pp. 586-591. [DOI] [Web of Science] [Pubmed]
Folli S., Westermann P., Braichotte D., Pèlegrin A., Wagnières G., van den Bergh H., Mach J.P., 1994. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Research 54(10) pp. 2643-2649. [Web of Science] [Pubmed]
Santoro L., Drouet C., Reboul A., Mach J.P., Colomb M.G., 1994. Covalent binding of C3b to monoclonal antibodies selectively up-regulates heavy chain epitope recognition by T cells. European Journal of Immunology 24(7) pp. 1620-1626. [DOI] [Web of Science] [Pubmed]
Terskikh A., Couty S., Pèlegrin A., Hardman N., Hunziker W., Mach J.P., 1994. Dimeric recombinant IgA directed against carcino-embryonic antigen, a novel tool for carcinoma localization. Molecular immunology 31(17) pp. 1313-1319. [DOI] [Web of Science] [Pubmed]
1993
Folli S., Pèlegrin A., Chalandon Y., Yao X., Buchegger F., Lienard D., Lejeune F., Mach J.P., 1993. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. International Journal of Cancer 53(5) pp. 829-836. [DOI] [Web of Science] [Pubmed]
Kurth M., Pèlegrin A., Rose K., Offord R.E., Pochon S., Mach J.P., Buchegger F., 1993. Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor. Journal of Medicinal Chemistry 36(9) pp. 1255-1261. [DOI] [Web of Science] [Pubmed]
Vogel C.A., Bischof-Delaloye A., Mach J.P., Pèlegrin A., Hardman N., Delaloye B., Buchegger F., 1993. Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts. British Journal of Cancer 68(4) pp. 684-690. [DOI] [Web of Science] [Pubmed]
Ychou M., Ricard M., Lumbroso J., Rougier P., Mach J.P., Buchegger F., Saccavini J.C., Lasser P., Elias D., Eschwege F., 1993. Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues. European Journal of Cancer 29A(8) pp. 1105-1111. [DOI] [Web of Science] [Pubmed]
1992
Buchegger F., Pèlegrin A., Hardman N., Heusser C., Lukas J., Dolci W., Mach J.P., 1992. Different behaviour of mouse-human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub-class in vivo. International Journal of Cancer 50(3) pp. 416-422. [DOI] [Web of Science] [Pubmed]
Chalandon Y., Mach J.P., Pèlegrin A., Folli S., Buchegger F., 1992. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations. Anticancer Research 12(4) pp. 1131-1139. [Web of Science] [Pubmed]
de Moraes J.Z., Carneiro C.R., Buchegger F., Mach J.P., Lopes J.D., 1992. Induction of an immune response through the idiotypic network with monoclonal anti-idiotype antibodies in the carcinoembryonic antigen system. Journal of Cellular Biochemistry 50(3) pp. 324-335. [DOI] [Web of Science] [Pubmed]
Mach J.P., Pèlegrin A., Folli S., Buchegger F., 1992. Les anticorps monoclonaux radiomarqués en tant que missiles anti-tumeurs, leurs succès diagnostiques, leur potentiel thérapeutique. Bulletin de l'Académie Nationale de Médecine 176(6) pp. 879-889. [Web of Science] [Pubmed]
Nap M., Hammarström M.L., Börmer O., Hammarström S., Wagener C., Handt S., Schreyer M., Mach J.P., Buchegger F., von Kleist S., 1992. Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen. Cancer Research 52(8) pp. 2329-2339. [Web of Science] [Pubmed]
1991
Buchegger F., Chalandon Y., Pèlegrin A., Hardman N., Mach J.P., 1991. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments. Journal of Nuclear Medicine 32(7) pp. 1414-1421. [Web of Science] [Pubmed]
Gallay P., Mach J.P., Carrel S., 1991. Characterization and detection of naturally occurring antibodies against IL-1 alpha and IL-1 beta in normal human plasma. European Cytokine Network 2(5) pp. 329-338. [Pubmed]
Hayoz D., Rimoldi D., Kühn L., Mach J.P., Carrel S., 1991. Cloning of an interferon-gamma regulated human melanoma-associated antigen: identity to the intercellular adhesion molecule ICAM-1. Melanoma Research 1(4) pp. 251-259. [Pubmed]
Mach J.P., Pèlegrin A., Buchegger F., 1991. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Current Opinion in Immunology 3(5) pp. 685-693. [DOI] [Web of Science] [Pubmed]
Matzku S., Mach J.P., Buchegger F., Moldenhauer G., Stadler M., Kalthoff H., 1991. Detachment of cell surface-bound anticarcinoembryonic antigen immune complexes by phospholipase C. Tumour Biology 12(5) pp. 272-278. [DOI] [Web of Science] [Pubmed]
Pèlegrin A., Folli S., Buchegger F., Mach J.P., Wagnières G., van den Bergh H., 1991. Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer 67(10) pp. 2529-2537. [DOI] [Web of Science] [Pubmed]
Westera G., Reist H.W., Buchegger F., Heusser C.H., Hardman N., Pfeiffer A., Sharma H.L., von Schulthess G.K., Mach J.P., 1991. Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nuclear Medicine Communications 12(5) pp. 429-437. [DOI] [Web of Science] [Pubmed]
1990
Buchegger F., Pèlegrin A., Delaloye B., Bischof-Delaloye A., Mach J.P., 1990. Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. Journal of Nuclear Medicine 31(6) pp. 1035-1044. [Web of Science] [Pubmed]
Mach J.P., Buchegger F., Pelegrin A., Ychou M., Ricard M., Lumbroso J., Rougier P., Lasser P., Elias D., Saccavini J.C., 1990. Radioimmunotherapy of colon carcinoma with I-131 labeled antibodies, successful experimental results and clinical dosimetry study. Pathologie-Biologie 38(8) p. 819. [Web of Science] [Pubmed]
Perey L., Hayes D.F., Tondini C., van Melle G., Bauer J., Lemarchand T., Reymond M., Mach J.P., Leyvraz S., 1990. Elevated CA125 levels in patients with metastatic breast carcinoma. British Journal of Cancer 62(4) pp. 668-670. [Document] [DOI] [Web of Science] [Pubmed]
1989
Audette M., Carrel S., Hayoz D., Giuffrè L., Mach J.P., Kühn L.C., 1989. A novel interferon-gamma regulated human melanoma-associated antigen, gp33-38, defined by monoclonal antibody Me14-D12. II. Molecular cloning of a genomic probe. Molecular Immunology 26(6) pp. 515-522. [DOI] [Web of Science] [Pubmed]
Barr I.G., Miescher S., von Fliedner V., Buchegger F., Barras C., Lanzavecchia A., Mach J.P., Carrel S., 1989. In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells. International Journal of Cancer 43(3) pp. 501-507. [DOI] [Web of Science] [Pubmed]
Bischof-Delaloye A., Delaloye B., Buchegger F., Gilgien W., Studer A., Curchod S., Givel J.C., Mosimann F., Pettavel J., Mach J.P., 1989. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. Journal of Nuclear Medicine 30(10) pp. 1646-1656. [Web of Science] [Pubmed]
Buchegger F., Pfister C., Fournier K., Prevel F., Schreyer M., Carrel S., Mach J.P., 1989. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments. Journal of Clinical Investigation 83(5) pp. 1449-1456. [Document] [DOI] [Web of Science] [Pubmed]
Hammarstrom S., Shively J.E., Paxton R.J., Beatty B.G., Larsson A., Ghosh R., Bormer O., Buchegger F., Mach J.P., Burtin P., 1989. Antigenic sites in carcinoembryonic antigen. Cancer Research 49(17) pp. 4852-4858. [Web of Science] [Pubmed]
Hardman N., Gill L.L., De Winter R.F., Wagner K., Hollis M., Businger F., Ammaturo D., Buchegger F., Mach J.P., Heusser C., 1989. Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen. International Journal of Cancer 44(3) pp. 424-433. [DOI] [Web of Science] [Pubmed]
Pochon S., Buchegger F., Pélegrin A., Mach J.P., Offord R.E., Ryser J.E., Rose K., 1989. A novel derivative of the chelon desferrioxamine for site-specific conjugation to antibodies. International Journal of Cancer 43(6) pp. 1188-1194. [DOI] [Web of Science] [Pubmed]
1988
Andres R.Y., Schubiger P.A., Tiefenauer L., Seybold K., Locher J.T., Mach J.P., Buchegger F., 1988. Immunoscintigraphic localization of inflammatory lesions: concept, radiolabelling and in vitro testing of a granulocyte specific antibody. European Journal of Nuclear Medicine 13(11) pp. 582-586. [DOI] [Web of Science] [Pubmed]
Behnke J., Mach J.P., Buchegger F., Carrel S., Delaloye B., De Tribolet N., 1988. In vivo localisation of radiolabelled monoclonal antibody in human gliomas. British Journal of Neurosurgery 2(2) pp. 193-197. [Pubmed]
Buchegger F., Vacca A., Carrel S., Schreyer M., Mach J.P., 1988. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. International Journal of Cancer 41(1) pp. 127-134. [DOI] [Web of Science] [Pubmed]
de Tribolet N., Frank E., Mach J.P., 1988. Monoclonal antibodies: their application in the diagnosis and management of CNS tumors. Clinical Neurosurgery 34 pp. 446-456. [Pubmed]
Giuffrè L., Schreyer M., Mach J.P., Carrel S., 1988. Cyclic AMP induces differentiation in vitro of human melanoma cells. Cancer 61(6) pp. 1132-1141. [DOI] [Web of Science] [Pubmed]
Knuth A., Kalthoff H., Wagener C., Zimmermann W., Kern H., Mach J.P., Douillard J.Y., Büchler M., 1988. Arbeitsgruppe "Tumorimmunologie": Tumorimmunologie des Gastrointestinaltraktes--Experimentelle und klinische Erfahrungen [The Tumor Immunology Study Group: tumor immunology of the gastrointestinal tract--experimental and clinical experiences]. Zeitschrift für Gastroenterologie. Verhandlungsband 23 pp. 238-251. [Pubmed]
1987
Buchegger F., Fournier K., Schreyer M., Carrel S., Mach J.P., 1987. Swine monoclonal antibodies of high affinity and specificity to carcinoembryonic antigen. Journal of the National Cancer Institute 79(2) pp. 337-342. [Web of Science] [Pubmed]
Carrel S., Isler P., Salvi S., Giuffrè L., Pantaleo G., Mach J.P., Cerottini J.C., 1987. Identification of a novel 45-kDa cell surface molecule involved in activation of the human Jurkat T cell line. European Journal of Immunology 17(10) pp. 1395-1402. [DOI] [Web of Science] [Pubmed]
Carrel S., Mach J.P., Miescher G., Salvi S., Giuffrè L., Schreyer M., Isler P., 1987. Phorbol 12-myristate 13-acetate induces surface expression of T3 on human immature T cell lines with and without concomitant expression of the T cell antigen receptor complex. European Journal of Immunology 17(8) pp. 1079-1087. [DOI] [Web of Science] [Pubmed]
Pulver M., Carrel S., Mach J.P., de Tribolet N., 1987. Cultured human fetal astrocytes can be induced by interferon-gamma to express HLA-DR. Journal of neuroimmunology 14(2) pp. 123-133. [DOI] [Web of Science] [Pubmed]
Wikstrand C.J., McLendon R.E., Carrel S., Kemshead J.T., Mach J.P., Coakham H.B., de Tribolet N., Bullard D.E., Zalutsky M.R., Bigner D.D., 1987. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. Journal of Neuroimmunology 15(1) pp. 37-56. [DOI] [Web of Science] [Pubmed]
1986
Buchegger F., Halpern S.E., Sutherland R.M., Schreyer M., Mach J.P., 1986. In vitro and in vivo tumor models for studies of distribution of radiolabelled monoclonal antibodies and fragments. Nuklearmedizin. Nuclear Medicine 25(6) pp. 207-209. [Web of Science] [Pubmed]
Carrel S., Giuffrè L., Vacca A., Salvi S., Mach J.P., Isler P., 1986. Monoclonal antibodies against idiotypic determinant(s) of the T cell receptor from HPB-ALL cells induce IL2 production in Jurkat cells without apparent evidence of binding. European journal of immunology 16(7) pp. 823-828. [DOI] [Web of Science] [Pubmed]
Carrel S., Isler P., Schreyer M., Vacca A., Salvi S., Giuffre L., Mach J.P., 1986. Expression on human thymocytes of the idiotypic structures (Ti) from two leukemia T cell lines Jurkat and HPB-ALL. European journal of immunology 16(6) pp. 649-652. [DOI] [Web of Science] [Pubmed]
Delaloye B., Bischof-Delaloye A., Buchegger F., von Fliedner V., Grob J.P., Volant J.C., Pettavel J., Mach J.P., 1986. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. Journal of Clinical Investigation 77(1) pp. 301-311. [Document] [DOI] [Web of Science] [Pubmed]
Girardet C., Vacca A., Schmidt-Kessen A., Schreyer M., Carrel S., Mach J.P., 1986. Immunochemical characterization of two antigens recognized by new monoclonal antibodies against human colon carcinoma. Journal of immunology 136(4) pp. 1497-1503. [Web of Science] [Pubmed]
Grob J.P., Mach J.P., Buchegger F., Schreyer M., Mosimann F., Besson A., Pettavel J., von Fliedner V., Bischof-Delaloye A., Delaloye B., 1986. Cancer detection by immunoscintigraphy, selection, and clinical application of monoclonal anti-CEA antibodies and their F(ab')2 or Fab fragments. Recent Results in Cancer Research 100 pp. 73-79. [Pubmed]
Locher J.T., Seybold K., Andres R.Y., Schubiger P.A., Mach J.P., Buchegger F., 1986. Imaging of inflammatory and infectious lesions after injection of radioiodinated monoclonal anti-granulocytes antibodies. Nuclear Medicine Communications 7(9) pp. 659-670. [Web of Science] [Pubmed]
Losa G.A., Heumann D., Carrel S., von Fliedner V., Mach J.P., 1986. Characterization of membrane vesicles circulating in the serum of patients with common acute lymphoblastic leukemia. Laboratory investigation 55(5) pp. 573-579. [Web of Science] [Pubmed]
Piguet V., Carrel S., Diserens A.C., Mach J.P., de Tribolet N., 1986. Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones. Journal of the National Cancer Institute 76(2) pp. 223-228. [Web of Science] [Pubmed]
1985
Buchsbaum D.J., Hanna D.E., Randall B.C., Buchegger F., Mach J.P., 1985. Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88Y and biodistribution studies. International Journal of Nuclear Medicine and Biology 12(2) pp. 79-82. [DOI] [Web of Science] [Pubmed]
de Muralt B., de Tribolet N., Diserens A.C., Stavrou D., Mach J.P., Carrel S., 1985. Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens. European journal of cancer and clinical oncology 21(2) pp. 207-216. [Web of Science] [Pubmed]
Heumann D., Carrel S., Morell A., Gratwohl A., Fopp M., Schneider P., Barras C., Mach J.P., von Fliedner V.E., 1985. Heterogeneity of Ia antigen expression on myeloblastic leukaemias: correlation with stage of maturation defined by cytochemical markers. British journal of haematology 59(4) pp. 681-687. [DOI] [Web of Science] [Pubmed]
Piguet V., Diserens A.C., Carrel S., Mach J.P., de Tribolet N., 1985. The immunobiology of human gliomas. Springer seminars in immunopathology 8(1-2) pp. 111-127. [Web of Science] [Pubmed]
1984
Carrel S., Buchegger F., Heumann D., Girardet C., Barras C., Losa G., Mach J.P., von Fliedner V., 1984. Detection of the common acute lymphoblastic leukemia antigen in the serum of leukemia patients. Journal of Clinical Investigation 74(5) pp. 1882-1885. [Document] [DOI] [Web of Science] [Pubmed]
Carrel S., Gross N., Heumann D., Sekaly R.P., Girardet C., Schmidt-Kessen A., Mach J.P., 1984. Monoclonal antibody against a "Pan-T-cell" antigen expressed by thymocytes, peripheral T-lymphocytes and T-cell leukemias. Molecular Immunology 21(10) pp. 831-840. [DOI] [Web of Science] [Pubmed]
de Tribolet N., Carrel S., Mach J.P., 1984. Brain tumor-associated antigens. Progress in Experimental Tumor Research 27 pp. 118-131. [Web of Science] [Pubmed]
De Tribolet N., Hamou M.F., Mach J.P., Carrel S., Schreyer M., 1984. Demonstration of HLA-DR antigens in normal human brain. Journal of neurology, neurosurgery, and psychiatry 47(4) pp. 417-418. [Document] [DOI] [Web of Science] [Pubmed]
Parmentier C., Lumbroso J., Schlumberger M., Gardet P., Mach J.P., Berche C., Rougier P., Caillou B., Tubiana M., 1984. Immunoscintigraphie avec tomographie d'émission dans les cancers de la thyroïde. Annales de Médecine Interne 135(5) pp. 345-350. [Web of Science] [Pubmed]
1983
Buchegger F., Haskell C.M., Schreyer M., Scazziga B.R., Randin S., Carrel S., Mach J.P., 1983. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. Journal of Experimental Medicine 158(2) pp. 413-427. [DOI] [Web of Science] [Pubmed]
Carrel S., Schmidt-Kessen A., Mach J.P., Heumann D., Girardet C., 1983. Expression of common acute lymphoblastic leukemia antigen (CALLA) on human malignant melanoma cell lines. Journal of Immunology 130(5) pp. 2456-2460. [Web of Science] [Pubmed]
de Muralt B., de Tribolet N., Diserens A.C., Carrel S., Mach J.P., 1983. Reactivity of antiglioma monoclonal antibodies for a large panel of cultured gliomas and other neuroectoderm derived tumors. Anticancer Research 3(1) pp. 1-6. [Web of Science] [Pubmed]
Girardet C., Ladisch S., Heumann D., Mach J.P., Carrel S., 1983. Identification by a monoclonal antibody of a glycolipid highly expressed by cells from the human myeloid lineage. International Journal of Cancer 32(2) pp. 177-183. [DOI] [Web of Science] [Pubmed]
Haskell C.M., Buchegger F., Schreyer M., Carrel S., Mach J.P., 1983. Monoclonal antibodies to carcinoembryonic antigen: ionic strength as a factor in the selection of antibodies for immunoscintigraphy. Cancer Research 43(8) pp. 3857-3864. [Web of Science] [Pubmed]
Heumann D., Colombatti M., Mach J.P., 1983. Human large granular lymphocytes contain an esterase activity usually considered as specific for the myeloid series. European Journal of Immunology 13(3) pp. 254-258. [DOI] [Web of Science] [Pubmed]
Lumbroso J., Berche C., Mach J.P., Rougier P., Aubry F., Buchegger F., Lasser P., Parmentier C., Tubiana M., 1983. Utilisation en tomoscintigraphie d'anticorps monoclonaux radio-marqués pour la détection chez l'homme des cancers digestifs et des cancers médullaires de la thyroïde. Bulletin du Cancer 70(2) pp. 96-102. [Web of Science] [Pubmed]
Mach J.P., Buchegger F., Forni M., Ritschard J., Carrel S., Egley R., Donath A., Rohner A., 1983. Immunoscintigraphy for the detection of human carcinoma after injection of radiolabeled monoclonal anti-carcinoembryonic antigen antibodies. Current Topics in Microbiology and Immunology 104 pp. 49-55. [Web of Science] [Pubmed]
Mach J.P., Chatal J.F., Lumbroso J.D., Buchegger F., Forni M., Ritschard J., Berche C., Douillard J.Y., Carrel S., Herlyn M. et al., 1983. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Research 43(11) pp. 5593-5600. [Web of Science] [Pubmed]
1982
Berche C., Mach J.P., Lumbroso J.D., Langlais C., Aubry F., Buchegger F., Carrel S., Rougier P., Parmentier C., Tubiana M., 1982. Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. British Medical Journal 285(6353) pp. 1447-1451. [DOI] [Web of Science] [Pubmed]
Buchegger F., Mettraux C., Accolla R.S., Carrel S., Mach J.P., 1982. Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen (CEA). Immunology Letters 5(2) pp. 85-91. [DOI] [Web of Science] [Pubmed]
Buchegger F., Phan M., Rivier D., Carrel S., Accolla R.S., Mach J.P., 1982. Monoclonal antibodies against carcinoembryonic antigen (CEA) used in a solid-phase enzyme immunoassay. First clinical results. Journal of Immunological Methods 49(2) pp. 129-139. [DOI] [Web of Science] [Pubmed]
Carrel S., Detribolet N., Mach J.P., 1982. Human melanoma-associated and glioma-associated antegen(S) identified by monoclonal-antibodies. Methods in Cancer Research 20 pp. 317-354. [Web of Science]
Carrel S., Schreyer M., Schmidt-Kessen A., Mach J.P., 1982. Reactivity spectrum of 30 monoclonal antimelanoma antibodies to a panel of 28 melanoma and control cell lines. Hybridoma 1(4) pp. 387-397. [DOI] [Web of Science] [Pubmed]
Long E.O., Gross N., Wake C.T., Mach J.P., Carrel S., Accolla R., Mach B., 1982. Translation and assembly of HLA-DR antigens in Xenopus oocytes injected with mRNA from a human B-cell line. EMBO Journal 1(5) pp. 649-654. [Web of Science] [Pubmed]
1981
Bonard E.C., Mach J.P., 1981. Antigène carcino-embryonnaire circulant, fortement élevé et persistant, sans cancer décelable. Schweizerische Medizinische Wochenschrift 111(48) pp. 1845-1849. [Web of Science] [Pubmed]
MacDonald H.R., Mach J.P., Schreyer M., Zaech P., Cerottini J.C., 1981. Flow cytofluorometric analysis of the binding of Vicia villosa lectin to T lymphoblasts: lack of correlation with cytolytic function. Journal of Immunology 126(3) pp. 883-886. [Web of Science] [Pubmed]
Mach J.P., Buchegger F., Forni M., Ritschard J., Berche C., Lumbroso J.D., Schreyer M., Girardet C., Accolla R.S., Carrel S., 1981. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunology Today 2(12) pp. 239-249. [DOI] [Web of Science]
von Fliedner V., Carrel S., Morell A., Heumann D., Losa G., Hirt A., Jeannet M., Mach J.P., Cruchaud A., 1981. Classification des leucémies aiguës par les marqueurs de surface et corrélation avec le diagnostic morphologique résultats sur 111 cas. Schweizerische Medizinische Wochenschrift 111(41) pp. 1524-1526. [Web of Science] [Pubmed]
1980
Accolla R.S., Carrel S., Mach J.P., 1980. Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines. Proceedings of the National Academy of Sciences of the United States of America 77(1) pp. 563-566. [DOI] [Web of Science] [Pubmed]
Capitaine Y., Voirol M., Lapp R., Mach J.P., Loizeau E., 1980. Variation en sens inverse des teneurs en antigène carcino-embryonnaire et en bicarbonates dans le suc duodénal de l'homme. Gastroentérologie Clinique et Biologique 4(3) pp. 200-205. [Web of Science] [Pubmed]
Carrel S., Accolla R.S., Carmagnola A.L., Mach J.P., 1980. Common human melanoma-associated antigen(s) detected by monoclonal antibodies. Cancer Research 40(7) pp. 2523-2528. [Web of Science] [Pubmed]
Conzelmann A., Pink R., Acuto O., Mach J.P., Dolivo S., Nabholz M., 1980. Presence of T 145 on cytolytic T cell lines and their lectin-resistant mutants. European Journal of Immunology 10(11) pp. 860-868. [DOI] [Web of Science] [Pubmed]
Dent P.B., Carrel S., Mach J.P., 1980. Detection of new cross-reacting carcinoembryonic antigen(s) on cultured tumor cells by mixed hemadsorption assay. Journal of the National Cancer Institute 64(2) pp. 309-316. [Web of Science] [Pubmed]
Mach J.P., Carrel S., Forni M., Ritschard J., Donath A., Alberto P., 1980. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. New England Journal of Medicine 303(1) pp. 5-10. [DOI] [Web of Science] [Pubmed]
Mach J.P., Forni M., Ritschard J., Buchegger F., Carrel S., Widgren S., Donath A., Alberto P., 1980. Use of limitations of radiolabeled anti-CEA antibodies and their fragments for photoscanning detection of human colorectal carcinomas. Oncodevelopmental Biology and Medicine 1(1) pp. 49-69. [Web of Science] [Pubmed]
Nabholz M., Conzelmann A., Acuto O., North M., Haas W., Pohlit H., von Boehmer H., Hengartner H., Mach J.P., Engers H. et al., 1980. Established murine cytolytic T-cell lines as tools for a somatic cell genetic analysis of T-cell functions. Immunological Reviews 51 pp. 125-156. [DOI] [Web of Science] [Pubmed]
1979
Carrel S., Gross N., Heumann D., Mach J.P., 1979. Expression of "Ia-like" antigens on cells from a human endometrial carcinoma cell line, END-1. Transplantation 27(6) pp. 431-433. [Web of Science] [Pubmed]
Carrel S., Gross N., Mach J.P., 1979. Reactivity of anti-Daudi serum with acute and chronic leukemias. Cancer Research 39(12) pp. 5171-5176. [Web of Science] [Pubmed]
1978
Cerottini J.C., Chapuis B., Mach J.P., Louis J., 1978. Aspects immunologiques du cancer bronchique. Therapeutische Umschau 35(12) pp. 988-992. [Web of Science] [Pubmed]
Jaquet H., Mach J.P., Pettavel J., 1978. Immunologische Methoden in der Tumordiagnostik [Immunological methods in tumor diagnosis]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin 84 pp. 567-572. [Pubmed]
Mach J.P., Vienny H., Jaeger P., Haldemann B., Egely R., Pettavel J., 1978. Long-term follow-up of colorectal carcinoma patients by repeated CEA radioimmunoassay. Cancer 42(3 Suppl) pp. 1439-1447. [DOI] [Web of Science] [Pubmed]
1977
Grob P.J., Barandun S., Carmann H., Cruchaud A., De Haller R., De Weck A., Fontana A., Frei P.C., Girard J.P., Hess M. et al., 1977. Klinisch-immunologische Teste--Standortbestimmung 1976. Schweizerische Medizinische Wochenschrift 107(11 Suppl) pp. 1995-1204. [Pubmed]
Mach J.P., Fritsche R., Phan M., Ozzello L., Stjernsward J., 1977. Search for biological markers in breast cancer. Progress in Clinical and Biological Research 12 pp. 91-108. [Pubmed]
1976
1975
Barrelet V., Mach J.P., 1975. Variations of the carcinoembryonic antigen level in the plasma of patients with gynecologie cancers during therapy. American Journal of Obstetrics and Gynecology 121(2) pp. 164-168. [Document] [Web of Science]
Jaeger P., Pettavel J., Wuilleret B., Bertholet M.M., Mach J.P., 1975. Utilité et limites du dosage de l'antigène carcinoembryonnaire (CEA) dans la surveillance postopératoire de malades atteints de carcinomes du côlon et du rectu. Schweizerische Medizinische Wochenschrift 105(46) pp. 1533-1538. [Web of Science] [Pubmed]
Mach J.P., 1975. Dépistage humoral du cancer. Sozial- und Präventivmedizin 20(3-4) pp. 135-141. [Pubmed]
Mach J.P., 1975. Diagnostic immunologique du cancer. Schweizerische Medizinische Wochenschrift 105(41) pp. 1301-1307. [Web of Science] [Pubmed]
Mach J.P., Singh K., Perrinjaquet J., Carrel S., Merenda C., MacDonald D., Holburn A., 1975. Relationship between carcinoembryonic antigen and blood group antigens A, B, and Lewis. Annals of the New York Academy of Sciences 259 pp. 389-403. [DOI] [Web of Science] [Pubmed]
Merenda C., Sordat B., Mach J.P., Carrel S., 1975. Human endometrial carcinomas serially transplanted in nude mice and established in continuous cell lines. International Journal of Cancer 16(4) pp. 559-570. [DOI] [Web of Science] [Pubmed]
1974
Cerottini J.C., Mach J.P., 1974. Cancer et immunité. Revue Médicale de la Suisse Romande 94(9) pp. 675-684. [Pubmed]
Holburn A.M., Mach J.P., MacDonald D., Newlands M., 1974. Studies of the association of the A, B and Lewis Blood group antigens with carcinoembryonic antigen (CEA). Immunology 26(4) pp. 831-843. [Web of Science] [Pubmed]
Mach J.P., Carrel S., Merenda C., Sordat B., Cerottini J.C., 1974. In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature 248(5450) pp. 704-706. [DOI] [Web of Science] [Pubmed]
Mach J.P., Jaeger P., Bertholet M.M., Ruegsegger C.H., Loosli R.M., Pettavel J., 1974. Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (C.E.A.). Lancet 304(7880) pp. 535-540. [DOI] [Web of Science] [Pubmed]
Mach J.P., Pusztaszeri G., MacDonald D., Bertholet M.M., 1974. Carcinoembryonic antigen (CEA). Use and limitations of the CEA radioimmunoassay in the diagnosis and follow-up of colo-rectal carcinoma. Johns Hopkins Medical Journal. Supplement 3 pp. 369-379. [Pubmed]
Ozzello L., Sordat B., Merenda C., Carrel S., Hurlimann J., Mach J.P., 1974. Transplantation of a human mammary carcinoma cell line (BT 20) into nude mice. Journal of the National Cancer Institute 52(5) pp. 1669-1672. [Document] [Web of Science] [Pubmed]
1973
Barandun S., Bütler R., Carmann H., de Haller R., de Weck A., Frei P.C., Girard J.P., Grob P.J., Hess M., Hitzig W. et al., 1973. Klinisch-immunologische Tests. Schweizerische Medizinische Wochenschrift 103(34) pp. 1195-1204. [Web of Science] [Pubmed]
Cerottini J.C., Mach J.P., Isliker H., 1973. L'utilité des tests immunologiques en cancérologie. Helvetica Chirurgica Acta 40(5) pp. 551-559. [Web of Science] [Pubmed]
Mach J.P., Holburn A., 1973. Immunochemistry and biochemistry of CEA. Annales d'Immunologie 124(4) pp. 579-581. [Web of Science] [Pubmed]
Mach J.P., Pusztaszeri G., Dysli M., Kapp F., Bierens de Haan B., Loosli R.M., Grob P., Isliker H., 1973. Dosage radio-immunologique de l'antigène carcinoembryonnaire (CEA) dans le plasma de malades atteints de carcinomes. Conclusion des premiers résultats d'une étude collaborative en Suisse. Schweizerische Medizinische Wochenschrift 103(10) pp. 365-371. [Web of Science] [Pubmed]
Pusztaszeri G., Mach J.P., 1973. Carcinoembryonic antigen (CEA) in non digestive cancerous and normal tissues. Immunochemistry 10(3) pp. 197-204. [DOI] [Web of Science] [Pubmed]
Waldman R.H., Rowe D.S., Mach J.P., 1973. Secretory IGA levels in serum of patients with various disorders. Clinical Medicine 80(11) pp. 11-13. [Web of Science]
1972
Mach J.P., Cerottini J.C., Isliker H., 1972. L'antigéne carcinoembryonnaire du tractus digestif humain. Son intêrêt dans le diagnostic de certains cancers. Schweizerische Medizinische Wochenschrift 102(9) pp. 309-312. [Web of Science] [Pubmed]
Pahud J.J., Mach J.P., 1972. Equine secretory IgA and secretory component. International Archives of Allergy and Applied Immunology 42(2) pp. 175-186. [Document] [Web of Science] [Pubmed]
1971
Aalund O., Blakeslee D., Butler J.E., Duncan J.R., Freeman M.J., Jenness R., Kehoe J.M., Mach J.P., Rapacz J., Vaerman J.P. et al., 1971. Proposed nomenclature for the immunoglobulins of the domesticated bovidae. Canadian Journal of Comparative Medicine 35(4) pp. 346-348. [Web of Science] [Pubmed]
Mach J.P., Pahud J.J., 1971. Secretory IgA, a major immunoglobulin in most bovine external secretions. Journal of Immunology 106(2) pp. 552-563. [Web of Science] [Pubmed]
1970
Waldman R.H., Mach J.P., Stella M.M., Rowe D.S., 1970. Secretory IgA in human serum. Journal of Immunology 105(1) pp. 43-47. [Web of Science] [Pubmed]
1969
Mach J.P., Pahud J.J., Isliker H., 1969. IgA with "secretory piece" in bovine colostrum and saliva. Nature 223(5209) pp. 952-955. [DOI] [Web of Science] [Pubmed]
 
 
 
 
 
 
 
Search:
 Go
 
rss/atom
youtube 

Contact

Mach_web2.jpg

Jean-Pierre Mach

Jean-Pierre.Mach@unil.ch

+ 41 21 692 5733

Chemin des Boveresses 155 - CH-1066 Epalinges  - Switzerland  -  Tel. +41 21 692 5700  -  Fax +41 21 692 5705
Swiss University